| Objective Functional dyspepsia(FD)is characterized by high incidence,diverse individual differences,long duration of disease,and high recurrence rate,which has a great impact on the physical health and quality of life of patients,but also causes difficulties in clinical treatment.At present,the proportion of the elderly FD patients is increasing,and the elderly have the particularity of multiple diseases coexistence,multiple medication,poor tolerance and other aspects.The treatment of FD in the elderly is mainly based on prokinetic drugs such as domperidone,mosapride,and trimebutine maleate,and the aim of this paper is to study the efficacy and safety of Oryz-Aspergillus Enzyme And Pancreatin Tablet combined with trimebutine maleate in the treatment of FD in elderly patients.MethodsUsing Rome IV diagnostic criteria,78 elderly FD patients admitted to the Affiliated Hospital of Qingdao University from December 2019 to October 2021 were selected as the study subjects and divided into the control group and the treatment group by random number table,39 cases in each group.The control group was treated with Trimebutine Maleate,orally 15 minutes before meals,0.1 g/time,3 times/d,for 30 days.The control group was treated with Oryz-Aspergillus Enzyme And Pancreatin Tablet,2 tablets/time,3times/d,for 30 days.The results of Alegre Dyspepsia Questionnaire(PADYQ)and Short Form Health Survey(SF-36)were compared between the two groups after 30 days of treatment,and the overall response rate was calculated according to the PADYQ score.ResultsIn the control group,the mean epigastric pain score decreased by about 18.55% from 6.36 to 5.18,the mean nausea score decreased by about 21.06% from 5.46 to 4.31,the mean vomiting score decreased by about 40.58%,the mean upper abdominal distension score decreased by about 32.18% from 1.74 to 1.18,and the mean early satiety score decreased by about 44.26% from 2.44 to 1.36 on the PADYQ score.On the SF-36 score,patients in the control group had an increase in mean PF score from 67.44 to 79.49,an increase of approximately 17.87%,an increase in mean RP score from 55.13 to 68.59,an increase of approximately 24.42%,an increase in mean BP score from 64.87 to 70.77,an increase of approximately 9.10%,an increase in mean VT score from 61.67 to 73.33,an increase of approximately 18.90%,an increase in mean RE score from 49.57 to 69.23,an increase of approximately 39.67%,an increase in mean MH score from 66.97 to 73.74,an increase of approximately 10.11%,an increase in mean SF score from 68.59 to 75.32,an increase of approximately 9.81%,and an increase in mean GH score from 63.72 to 75.64,an increase of approximately 18.71%.Observe,on the PADYQ score,the mean epigastric pain score of patients decreased from 6.79 to 4.49,with a decrease of about 33.87%,the mean nausea score decreased from 5.62 to 3.69,with a decrease of about 34.34%,the mean vomiting score decreased from 6.62 to 3.49,with a decrease of about 47.28%,the mean upper abdominal distension score decreased from 1.49 to 0.87,with a decrease of about41.61%,and the mean early satiety score decreased from 2.62 to 0.90,with a decrease of about 65.65%.On the SF-36 score,the mean PF score of observer patients increased from66.41 to 75.38,an increase of about 13.51%,the mean RP score increased from 57.05 to69.23,an increase of about 21.35%,the mean BP score increased from 65.90 to 76.92,an increase of about 16.72%,the mean VT score increased from 61.15 to 72.44,an increase of about 18.46%,the mean RE score increased from 45.29 to 67.52,an increase of about49.08%,the mean MH score increased from 65.74 to 81.74,an increase of about 24.34%,the mean SF score increased from 73.08 to 83.01,an increase of about 13.59%,and the mean GH score increased from 68.72 to 84.23,an increase of about 22.57%.The PADYQ symptom score of the treatment group after treatment was significantly lower than that of the control group,and the difference had statistical significance(P < 0.05);the SF-36 score of the treatment group after treatment was higher than that of the control group in four dimensions of BP,MH,SF and GH,and the difference had statistical significance(P< 0.05);the overall response rate of the treatment group was 87.2%,higher than 64.1% of the control group,and the difference had statistical significance(P < 0.05);the incidence rate of clinical adverse reactions of the treatment group was 2.56%,compared with 5.13%of the control group,the difference had no statistical significance(P > 0.05).Conclusion(1)Trimebutine maleate can effectively reduce the clinical symptoms of elderly FD patients and improve the quality of life of patients.(2)Oryz-Aspergillus Enzyme And Pancreatin Tablet combined with trimebutine maleate can effectively promote the physical and mental health of elderly FD patients and significantly improve the effective rate of clinical treatment.(3),the combination of the above two drugs does not increase the occurrence of adverse reactions and has good safety. |
PDF Full Text Request